[go: up one dir, main page]

IN2012DN03449A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03449A
IN2012DN03449A IN3449DEN2012A IN2012DN03449A IN 2012DN03449 A IN2012DN03449 A IN 2012DN03449A IN 3449DEN2012 A IN3449DEN2012 A IN 3449DEN2012A IN 2012DN03449 A IN2012DN03449 A IN 2012DN03449A
Authority
IN
India
Prior art keywords
heteroary
alkyl
formula
disclosed
optionally substituted
Prior art date
Application number
Inventor
Nicholas Cook Brian
Kuzmich Daniel
Mao Can
Razavi Hossein
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43126891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IN2012DN03449A publication Critical patent/IN2012DN03449A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are CCRI receptor antagonists of the formula (1),wherein X is nitorgen or, C-R.; Ar1 is carbocyele, heteroary or heterocyclyl each optionally substituted by one to three Ra; Ar2 is earboeyele, heteroary or heterocyely, each optionally substituted by one to two R1 is hydrogen, C16 alkyl or C1-6 alkoxyC 1-6 alkyl, Also disclosed are compositions, methods of making and using compounds of the formula (1).
IN3449DEN2012 2009-10-21 2010-10-19 IN2012DN03449A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25359009P 2009-10-21 2009-10-21
PCT/US2010/053142 WO2011049917A1 (en) 2009-10-21 2010-10-19 Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists

Publications (1)

Publication Number Publication Date
IN2012DN03449A true IN2012DN03449A (en) 2015-10-23

Family

ID=43126891

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3449DEN2012 IN2012DN03449A (en) 2009-10-21 2010-10-19

Country Status (30)

Country Link
US (1) US9056858B2 (en)
EP (1) EP2491028B1 (en)
JP (1) JP5542946B2 (en)
KR (1) KR20120087923A (en)
CN (1) CN102666526A (en)
AP (1) AP2012006204A0 (en)
AU (1) AU2010308277A1 (en)
BR (1) BR112012009331A2 (en)
CA (1) CA2778060A1 (en)
CL (1) CL2012000967A1 (en)
CO (1) CO6531488A2 (en)
DK (1) DK2491028T3 (en)
EA (1) EA021015B1 (en)
EC (1) ECSP12011904A (en)
ES (1) ES2444780T3 (en)
GE (1) GEP20146103B (en)
HR (1) HRP20140213T1 (en)
IL (1) IL218823A0 (en)
IN (1) IN2012DN03449A (en)
MA (1) MA33675B1 (en)
MX (1) MX2012004644A (en)
NZ (1) NZ599132A (en)
PE (1) PE20121433A1 (en)
PH (1) PH12012500775A1 (en)
PL (1) PL2491028T3 (en)
PT (1) PT2491028E (en)
RS (1) RS53130B (en)
SI (1) SI2491028T1 (en)
TN (1) TN2012000180A1 (en)
WO (1) WO2011049917A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285783B1 (en) 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Indazole compounds as ccr1 receptor antagonists
EP2297112B1 (en) 2008-05-06 2013-04-03 Boehringer Ingelheim International GmbH Pyrazole compounds as ccr1 antagonists
NZ591115A (en) 2008-09-26 2012-10-26 Boehringer Ingelheim Int Azaindazole compounds as ccr1 receptor antagonists
IN2012DN03449A (en) 2009-10-21 2015-10-23 Boehringer Ingelheim Int
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
EP2563787B1 (en) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazole amide compounds as ccr1 receptor antagonists
JP5684406B2 (en) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrazolopiperidine compounds as CCR1 receptor antagonists
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
PT3131902T (en) 2014-04-14 2019-09-17 Boehringer Ingelheim Int Compounds as modulators of ror gamma
CN112707831A (en) * 2021-02-05 2021-04-27 阿里生物新材料（常州）有限公司 Synthetic method of 3- (1-aminocyclopropyl) methyl benzoate
WO2025248032A1 (en) 2024-05-31 2025-12-04 Syngenta Crop Protection Ag Pesticidally active indazole compounds

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
CA1338625C (en) 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
UA45944C2 (en) 1991-03-28 2002-05-15 Ейсай Ко., Лтд Heterocycle-amino cyclic derivatives or pharmaceutically acceptable salts, intermediates, pharmaceutical compositions, method for inhibiting cholinesterase, METHOD FOR PRODUCING heterocycle-amino cyclic derivatives
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
CA2116863A1 (en) 1992-07-03 1994-01-20 Sumio Yokota Condensed heterocyclic derivatives and herbicides
AU674240B2 (en) 1993-06-25 1996-12-12 Ihara Chemical Industry Co. Ltd. Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof
JPH10509721A (en) 1994-12-06 1998-09-22 メルク シヤープ エンド ドーム リミテツド Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
GB9519563D0 (en) 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
AU1345697A (en) 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
JPH101478A (en) 1996-06-11 1998-01-06 Kumiai Chem Ind Co Ltd Indazole sulfonylurea derivatives and herbicides
GB9615449D0 (en) 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
YU25400A (en) 1997-11-04 2003-07-07 Pfizer Products Inc. Therapeutically active compounds based on indazole
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
WO2001000656A2 (en) 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
JP4614039B2 (en) 2000-03-02 2011-01-19 エヌディーシー・インフラレッド・エンジニアリング・リミテッド Electromagnetic detection device
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US7058826B2 (en) 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
ATE455104T1 (en) 2001-11-01 2010-01-15 Icagen Inc PYRAZOLAMIDE FOR USE IN THE TREATMENT OF PAIN
WO2008011131A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
DE60332717D1 (en) 2002-04-11 2010-07-08 Boehringer Ingelheim Pharma Heterocyclic amide derivatives as cytokine inhibitors
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
EP1531822B1 (en) 2002-06-12 2009-08-05 ChemoCentryx Inc 1-aryl-4-substituted piperazine derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders
CA2494942A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (en) 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
ATE423122T1 (en) 2003-08-15 2009-03-15 Astrazeneca Ab CONDENSED HETEROCYCLES AS INHIBITORS OF GLUTAMATRACEMASE (MURI)
AU2006216917A1 (en) 2005-02-24 2006-08-31 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
PL1881823T3 (en) 2005-05-17 2015-05-29 Sarcode Bioscience Inc COMPOSITIONS AND METHODS OF EYE DISEASES TREATMENT
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
EP1906965B1 (en) * 2005-06-22 2015-05-06 ChemoCentryx, Inc. Azaindazole compounds and methods of use
PT1924561E (en) 2005-09-01 2013-01-16 Lilly Co Eli 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
EP1940394A4 (en) * 2005-10-25 2009-07-08 Smithkline Beecham Corp Chemical compounds
BRPI0806898A2 (en) 2007-01-19 2015-07-14 Ardea Biosciences Inc Mek inhibitors
CN101687864A (en) * 2007-06-26 2010-03-31 阿斯利康(瑞典)有限公司 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors
WO2009037570A2 (en) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
SI2225238T1 (en) 2007-11-29 2014-12-31 Boehringer Ingelheim International Gmbh Derivatives of 6,7-dihydro-5h-imidazoy1,2- imidazole-3- carboxylic acid amides
EP2285783B1 (en) 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Indazole compounds as ccr1 receptor antagonists
EP2297112B1 (en) 2008-05-06 2013-04-03 Boehringer Ingelheim International GmbH Pyrazole compounds as ccr1 antagonists
NZ591115A (en) 2008-09-26 2012-10-26 Boehringer Ingelheim Int Azaindazole compounds as ccr1 receptor antagonists
IN2012DN03449A (en) 2009-10-21 2015-10-23 Boehringer Ingelheim Int
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
BR112012013582A2 (en) 2009-12-08 2016-07-05 Boehringer Ingelheim Int process for synthesis of intermediates useful for the production of substituted indazole and azaindazole compounds
EP2563787B1 (en) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazole amide compounds as ccr1 receptor antagonists
JP5684406B2 (en) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrazolopiperidine compounds as CCR1 receptor antagonists

Also Published As

Publication number Publication date
US9056858B2 (en) 2015-06-16
JP5542946B2 (en) 2014-07-09
PT2491028E (en) 2014-02-04
RS53130B (en) 2014-06-30
PH12012500775A1 (en) 2012-11-26
PE20121433A1 (en) 2012-11-10
HRP20140213T1 (en) 2014-04-11
NZ599132A (en) 2014-05-30
TN2012000180A1 (en) 2013-12-12
SI2491028T1 (en) 2014-03-31
EP2491028B1 (en) 2013-12-11
MX2012004644A (en) 2012-05-08
GEP20146103B (en) 2014-05-27
AU2010308277A1 (en) 2012-04-26
CN102666526A (en) 2012-09-12
EA021015B1 (en) 2015-03-31
CO6531488A2 (en) 2012-09-28
AP2012006204A0 (en) 2012-04-30
JP2013508376A (en) 2013-03-07
US20120270870A1 (en) 2012-10-25
WO2011049917A1 (en) 2011-04-28
ECSP12011904A (en) 2012-10-30
PL2491028T3 (en) 2014-05-30
EA201200602A1 (en) 2012-12-28
MA33675B1 (en) 2012-10-01
BR112012009331A2 (en) 2019-09-24
EP2491028A1 (en) 2012-08-29
IL218823A0 (en) 2012-06-28
KR20120087923A (en) 2012-08-07
CA2778060A1 (en) 2011-04-28
DK2491028T3 (en) 2014-01-13
CL2012000967A1 (en) 2012-09-14
ES2444780T3 (en) 2014-02-26

Similar Documents

Publication Publication Date Title
IN2012DN03449A (en)
MX2010004028A (en) 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one.
NI201100011A (en) PYRIDINE DERIVATIVES - PYRIDINONES, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
ATE429427T1 (en) PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
PA8774201A1 (en) RECEIVER ANTAGONIST
CU20100115A7 (en) USEFUL INTERMEDIATES FOR THE PREPARATION OF CARBOXAMIDE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC RECEIVER
MX2013001234A (en) Deuterated tandospirone derivatives as 5-ht1a receptor agonists.
MX381002B (en) ALKYLAMIDO COMPOUNDS AND THEIR USES.
MX2013005833A (en) Novel fused pyridine compounds as casein kinase inhibitors.
EA201290355A1 (en) SPYROPYPERIDINE CONNECTIONS AS ANTAGONISTS OF ORL-1 RECEPTOR
UY32553A (en) NEW DERIVATIVES OF PIRROLIDINADIONA ESPIROHETEROCÍCLICOS 3-REPLACED
CR11157A (en) DERIVATIVES OF 7-ALQUINIL-1,8-NAFTIRIDONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
MA32957B1 (en) QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS
UY30534A1 (en) DERIVATIVES OF 5,6-BISARIL-2-PIRIDIN-CARBOXAMIDE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS ANTAGONISTS OF UROTENSIN II RECEPTORS
MX2013006420A (en) Hydroxylated aminotriazole derivatives as alx receptor agonists.
MX2010004498A (en) Cyclohexeneamide derivatives and their use as trpv1 antagonist.
UA105767C2 (en) Amorphous prothioconazole, microbicidal composition based thereon, process for the preparation thereof
EA200700365A1 (en) INDOL-2-CARBOXAMIDINE DERIVATIVES AS ANTAGONISTS OF NMDA RECEPTOR
UY33528A (en) DERIVATIVES OF OXADIAZOLS AND PIRIDAZINES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
EA201170585A1 (en) IZOHINOLINON DERIVATIVES AS ANTAGONISTS NK3
MA32479B1 (en) Compounds new active as muscarinic receptor antagonists
EA201001870A1 (en) NEW CRYSTAL SHAPES OF SODIUM CRUST TUNE
CL2012000159A1 (en) Procedure for the stereoselective preparation of compounds (trans) - and (cis) -9- [4- (3-chloro-2-fluoro-phenylamino) -7-methoxy-quinazolin-6-yloxy] -1,4-diaza- spiro [5.5] undecan-5-one, and the intermediate compounds considered.
IN2012DN01661A (en)
MX2012007385A (en) Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists.